SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

LDN-27219

Cat. No.: HY-16693

CAS No.: 312946-37-5

Molecular Formula: $C_{20}H_{16}N_4O_2S_2$

Molecular Weight: 408.5

Target: Others

Pathway: Others

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (244.80 mM; Need ultrasonic)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	2.4480 mL	12.2399 mL	24.4798 mL
5 mM	0.4896 mL	2.4480 mL	4.8960 mL
10 mM	0.2448 mL	1.2240 mL	2.4480 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (6.12 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.08 mg/mL (5.09 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (5.09 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

LDN-27219 is a reversible, slow-binding inhibitor of TGase. LDN-27219 inhibits human TGase with an IC_{50} value of 0.6 μM. LDN-27219 effectively decreases blood pressure and induces vasodilation, it can be used for the research of cardiovascular disease[1][2].

IC_{50} & Target

IC50: 0.6 μM (hTGase)[1]

In Vitro

LDN-27219 (30 μM; 12 min) promotes the closed conformation of TGase 2 to activates calcium-activated potassium channels

in smooth muscle cells[2].
?LDN-27219 (30 μM; 20-25 min) increases the response to acetylcholine in phenylephrine-contracted human subcutaneous arteries[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

LDN-27219 (0.1-2 mg/kg; i.v. once) affects vivo arterial pressure and shows larger effects on older rats[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	12 to 14-week-old male Wistar rats[2]
Dosage:	0.1, 1 and 2 mg/kg
Administration:	Intravenous injection; 0.1, 1 and 2 mg/kg once
Result:	Dose-dependently decreased mean arterial pressure of mice.

Animal Model:	12 to 14- and 35 to 40-week-old male Wistar rats
Dosage:	0.1, 1 and 2 mg/kg
Administration:	Intravenous injection; 0.1, 1 and 2 mg/kg once
Result:	Decreased mean arterial pressure in old group more significant than young group.

CUSTOMER VALIDATION

- JCI Insight. 2023 Oct 9;8(19):e160374.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Pinilla E, et al. Transglutaminase 2 Inhibitor LDN 27219 Age-Dependently Lowers Blood Pressure and Improves Endothelium-Dependent Vasodilation in Resistance Arteries. Hypertension. 2021 Jan;77(1):216-227.

[2]. Case A, et al. Kinetic analysis of the interaction of tissue transglutaminase with a nonpeptidic slow-binding inhibitor. Biochemistry. 2007 Jan 30;46(4):1106-15.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA